Cancer Immunotherapeutics In the News
Australian lobster fisherman David Thompson traveled 9,000 miles for treatment at City of Hope after being diagnosed with Stage 4 oropharyngeal cancer. Given just six weeks to live, he is thriving more than a year after participating in an immunotherapy clinical trial.
Longtime "Jeopardy" host Alex Trebek was diagnosed with Stage 4 pancreatic cancer. Susanne Gray Warner, M.D., a surgical oncologist at City of Hope, tells us what you need to know regarding the disease, which is the third-leading cause of cancer death.
Stephen J. Forman, M.D., the renowned leader of the Hematologic Malignancies and Stem Cell Transplantation Institute and the Francis & Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation, will receive the 2019 DKMS Mechtild Harf Science Award in honor of his outstanding achievements in cancer immunology, hematology, stem cell transplantation and CAR T cell therapy.
City of Hope has long been renowned for its expertise in treating cancer and diabetes. But specialists here also are tackling lesser-known but equally devastating diseases that may or may not have an oncologic component.
City of Hope has earned its third Lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute, which provides $12.5 million for research.
An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence (SPORE) grant from the National Cancer Institute (NCI), one of four current NCI-supported lymphoma SPOREs. The grant covers a five-year period and totals $12.5 million.
Vanessa Jonsson, Ph.D., focuses on chimeric antigen receptor (CAR) T cell therapy. Using such tools as computational analysis and mathematical modeling, she examines the complex interactions between the tumor, the patient’s immune system and the therapy to learn how the tumor evades the immune response.
In the three decades since robots first entered the operating room, these increasingly sophisticated machines have helped surgeons perform more than a million procedures, all over the human body.
What's it like to work at the center of a true medical and scientific revolution? It's emotional, often overwhelming. But it’s also a place to witness miracles. Such is the life of the clinical research nurses who staff City of Hope's CAR T cell program.
Meet float rider Cheryl Wiers, a wife and mother of two who battled cancer twice only to have it return. She eventually found prolonged remission thanks to a CAR T Cell therapy offered at City of Hope.
City of Hope clinical and laboratory investigators presented leading-edge research, including new targets in CAR T cell therapy, at the 60th annual ASH meeting in San Diego.
Xiuli Wang, Ph.D., research professor at City of Hope, presented encouraging research on using CAR T cell therapy for central nervous system lymphoma at this year's American Society of Hematology conference.
Physicians and researchers at the 2018 American Society of Hematology conference presented clinical trials for new leukemia and lymphoma treatments, laying the groundwork for innovative therapeutic approaches aimed at improving treatment options and quality of life for patients.
City of Hope physicians and researchers at the American Society of Hematology (ASH) meeting in San Diego presented clinical trials for novel leukemia and lymphoma treatments that could improve outcomes for patients.
CAR T cell therapy is one of the most promising new approaches for treating cancer today. Come spend a day learning more about CAR T cell therapy from City of Hope’s resident experts to better understand what is now at the forefront of oncology treatment.
City of Hope announced today that it will present data on new findings on immunotherapies, including CAR T cell therapy, bone marrow transplants and other treatments for blood cancers, at the American Society of Hematology (ASH) Annual Meeting Dec. 1-4 in San Diego.
City of Hope, TGen announce letter of intent to build cell therapy manufacturing facility in Phoenix. The move would enable the organizations to meet a demand for clinical cell therapies that is expected to grow 42 percent annually over the next decade.
City of Hope is now enrolling patients in a phase 1 trial evaluating the safety and efficacy of CAR T cell therapy in patients with HER2+ breast cancer that has metastasized to the brain.
A new City of Hope chimeric antigen receptor (CAR) T cell trial – the first to focus on HER2-postive breast cancer patients with brain metastases – is now enrolling potential participants.
Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge. The immunotherapy trial is the first to deliver CAR T cells directly to the brain of HER2-positive breast cancer patients with brain metastases.
Harnessing the power of CAR T cells
The scientists developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses – a two-step immunotherapy that eliminated difficult-to-treat prostate cancer in experimental models
The California Institute for Regenerative Medicine today awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop CAR T cells that can target and kill HIV-infected cells. The treatment will also use the cytomegalovirus vaccine to stimulate the immune system to proliferate and maintain the CAR T cells.
The California Institute for Regenerative Medicine has awarded City of Hope’s Xiuli Wang, Ph.D., $3.8 million to develop chimeric antigen receptor (CAR) T cells that can target and kill HIV-infected cells.
City of Hope’s Stephen J. Forman, M.D., is now an official member of the Parker Institute for Cancer Immunotherapy.